Nasseo, Inc. ("Nasseo") is a medical device company that has developed a proprietary implant surface modification technology to create the next generation of dental and orthopedic implants. While current standard of care implants have been widely used throughout the world, they suffer from failures and can be improved to promote osseointegration, soft tissue integration, lower inflammation, and lower bacterial colonization. Nasseo's groundbreaking platform technology directly alters the natural oxide layer of the implant surface at the molecular level to create uniform and patterned structures that enhance implant performance and is not a coating. The Company’s Board of Advisors and Clinicians includes internationally renowned experts in the fields of biomaterials, oral surgery, dental implants, orthopedics, regulatory processes, sales, marketing, and business development.
Nasseo's TiArray™ Dental Implant System received FDA 510(k) regulatory clearance in August 2013 and is cleared for sale in the US. With the FDA clearance, Nasseo is continuing to increase the value of its proprietary technology by conducting additional pre-clinical and clinical studies with key opinion leaders at leading centers, including Dr. David Cochran of the University of Texas Health Science Center at San Antonio (UTHSCSA).
Nasseo's technology was initially developed in collaboration with the University of California, San Diego's Bioengineering and Materials Science Departments as well as the Bio-Implant Laboratory at the Lund University in Sweden. During the course of the 10+ year R&D period, the technology received over $1.5M in grant funding from the US ARMY and industry leaders. Nasseo has additionally closed on a $520K seed financing round that was led by a renowned dental clinician and the BioAccel/BioInspire medical device incubator, received a $250K grant for winning the ACA’s 2013 Arizona Innovation Challenge, and closed on a $1.2M Series A financing round that was led by the institutional investor Green Park & Golf Ventures and leading individual investors and clinicians including Tom Baruch of Formation 8. Nasseo will utilize the Series A funding to conduct pre-clinical and clinical studies that focus on key benefits of Nasseo’s groundbreaking platform technology. Currently, the company is entertaining further investment offers and partnership opportunities, both domestically and internationally.
For more information regarding Nasseo, Inc., please contact us.